Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.

Tack JanVincenzo StanghelliniFermín MearinYan YiannakouPeter LayerBenoit CoffinMagnus SimrenJonathan MackinnonGwen WisemanAnne Marciniaknull null

Published in: BMC gastroenterology (2019)

IBS-C is not a life-threatening condition; however, it has large impact on healthcare systems and society. Direct and indirect costs for moderate to severe IBS-C were high with the largest direct cost driver being hospitalisations/ER visits.

Keyphrases

irritable bowel syndrome
healthcare
high intensity
early onset
drug induced
estrogen receptor